Dexamethasone - Otonomy
Alternative Names: OTIVIDEX; OTO-104; Sustained release dexamethasoneLatest Information Update: 14 Jan 2022
At a glance
- Originator Otonomy; University of California
- Developer Otonomy
- Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Meniere's disease; Sensorineural hearing loss
Most Recent Events
- 22 Feb 2021 Efficacy data from the phase III trial for Meniere's disease released by Otonomy
- 01 Feb 2021 Discontinued - Phase-II for Meniere's disease (In the elderly, In adults) in Canada (Intratympanic)
- 01 Feb 2021 Discontinued - Phase-II for Sensorineural hearing loss (In adolescents, In children, In infants, In adults) in USA (Intratympanic)